Showing results (131-140 of 2,336) with videos related to
Sort By:
Pageof 234
Clinical Lung Cancer|January 8, 2013
Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trialSung Yong Lee, Hee Sun Park, Kye Young Lee, et al.Clinical Lung Cancer|January 15, 2013
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinibJin Hyun Park, Tae Min Kim, Bhumsuk Keam, et al.Clinical Lung Cancer|December 25, 2012
Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancerDavid J Sher, Benjamin T Gielda, Michael J Liptay, et al.Clinical Lung Cancer|February 9, 2013
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II studyDavid R Spigel, David M Waterhouse, Steve Lane, et al.Clinical Lung Cancer|June 25, 2013
The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinomaTomonari Kinoshita, Junji Yoshida, Genichiro Ishii, et al.Clinical Lung Cancer|July 30, 2013
Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years)Paul D Aridgides, Adam Janik, Jeffrey A Bogart, et al.Clinical Lung Cancer|July 30, 2013
Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancerShih-Hsin Hsiao, Chi-Li Chung, Chi-Ming Lee, et al.Clinical Lung Cancer|April 20, 2012
Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical centerJeffrey T Yorio, Jingsheng Yan, Yang Xie, et al.Clinical Lung Cancer|December 16, 2005
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?David Raben, Anderson RyanClinical Lung Cancer|December 16, 2005
The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapyAlex A AdjeiPageof 234